CSCI

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX:CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited ("Wuzhou") for the commercialization of Macrilen® (macimorelin) in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan. Under the terms of the agreement, Wuzhou will be responsible for the registration, importation, and commercialization of Macril

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX:CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company's board of directors (the "Board"), has been appointed Interim Chief Executive Officer, effective immediately. Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer. "As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition lea

COSCIENS voluntarily delists from Nasdaq, while retaining the Company's listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3 2024. TORONTO, ONTARIO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (FINRA: CSCIF) (TSX:CSCI) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical solutions, today reported its financial and operating results for the third quarter ended September 30, 2025 and provided a corporate update regarding operational and strategic developments during the quarter. "Our focus in Q3 was to ensure the zero-based budgeting and restructuring p

25 - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical solutions, today reported its financial and operating results for the second quarter ended June 30, 2025 and provided a corporate update following significant operational and strategic developments during the quarter. Q2 2025 Highlights Revenue increased by 17% compared to Q2 2024Q2 Gross profit increased by 19% compared to Q2 2024Operating expenses reduced by

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI, TSX:CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of Nominee Votes For  % For  Votes Against  % Against Peter H. Puccetti (Chair)  580,289   88.92%  72,286   11.08%Anthony J.

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI, TSX:CSCI) today announced that it has entered into a resolution agreement (the "Resolution Agreement") with Goodwood Inc., Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") to resolve matters relating to the upcoming annual and special meeting of COSCIENS' shareholders that had been scheduled to be held on June 26, 2025 (the "2025 Annual Meeting"). Pursuant to the Resolution Agreement, COSCIENS has today implemented a consensual reconstitution of its board of directors designed to best position COSCIENS to create value for all its shareholde

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.("Goodwood") regarding six (6) director nominations for the Company's upcoming Annual and Special Meeting of Shareholders. "We respectfully acknowledge receipt of the statement regarding the intentions from Goodwood and are carefully reviewing its contents," said Ronnie Miller, Chair of the Board of COSCIE

New Director Nominees are Strong Leaders to Revitalize COSCIENS TORONTO, May 23, 2025 /CNW/ - Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") announced today that Goodwood has notified COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) that Goodwood intends to nominate six new highly qualified and experienced directors (the "Shareholder Nominees") for election at the upcoming annual and special meeting of COSCIENS' shareholders (the "Meeting") scheduled to be held on June 26, 2025. Goodwood beneficially owns, directly or indirectly, an aggregate of 257,257 common shares of COSCIENS, or approximately 8.2% of COSCIENS' outstanding common shares. On December 19, 2024,

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash Advancing Phase 2 clinical trial with Avenanthramide product Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, Gilles Gagnon to remain as a Strategic Advisor and Director Company leveraging core competencies to develop and commercializenatural-based products to improve health and wellness TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the appointment of Anna B

20-F - COSCIENS Biopharma Inc. (0001113423) (Filer)

6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)